ECTOPIA stands for: Elimination of ventricular premature beats with CaTheter ablation versus OPtImal Anti-arrhythmic drug treatment
The ECTOPIA trial aims to compare the efficacy of AAD (flecainide/verapamil and sotalol) and catheter ablation in reducing VPB burden after 3 months in patients with frequent symptomatic idiopathic VPB/VT.
The primary endpoint is defined as successful therapy, defined as >80 % reduction of VPB/VT burden and expressed in % of 24-hours ambulatory Holter monitoring period, after 3 months.
The ECTOPIA trial is a national, multicenter, prospective, randomized clinical trial designed to enroll 180 patients in up to 6 centers in The Netherlands.
The first patient was included in the Isala hospital in the Netherlands on February 12, 2019.
The principal investigator is Arif Elvan MD, PhD (cardiologist-electrophysiologist Isala, Zwolle, The Netherlands).